Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection.
about
Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsValganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipientsCytomegalovirus pneumonia in hematopoietic stem cell recipients.Cytomegalovirus pneumonitis and bone marrow transplantation: identification of a specific high risk groupHow we treat cytomegalovirus in hematopoietic cell transplant recipients.Early infections in adult patients undergoing unrelated donor cord blood transplantation.Viral infections in leukemia and bone marrow transplant patients.Herpes virus infections in immunocompromised patients: problems and therapeutic interventions.Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis.Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
P2860
Q34294838-704144BB-1D14-4031-BB60-7342FB54FEB2Q35553386-01131D2C-4BEF-4189-B268-5B46E39EF078Q35871893-502E1FB6-0ADA-440A-9DFF-A91EFF20470AQ37091613-C8390ED7-0FB2-4348-9667-9A73A13204ECQ37179131-2483B28E-C001-461E-B4ED-4A6FFE56D387Q37234440-DC942720-6547-4C29-B450-3F92972C3D81Q37237427-64C81DBC-921B-48BA-96F5-B6B6282C7533Q40569370-97A82C17-35C0-4252-8D76-333E4C27341CQ40722959-A68AC13C-2978-49B6-84FA-123F678FCE9FQ40769917-0290F04F-A22D-4001-8FFA-95A8361D1A31Q41557335-1B2FD631-B727-4B8C-A47A-8E51BC6042EBQ41668011-87779DD9-0012-402B-8455-749EEE6F87EAQ44245126-CF537F9F-B4AA-456B-A212-B3AF850206EBQ44431125-4B4C58C5-AF53-41C7-A90C-B5471B6C6196Q46884993-35F0080F-7440-4F87-8653-E15A4718D31F
P2860
Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@ast
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@en
type
label
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@ast
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@en
prefLabel
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@ast
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@en
P2093
P2860
P1476
Prophylactic use of ganciclovi ...... cal cytomegalovirus infection.
@en
P2093
Atkinson K
Concannon A
Marshall G
P2860
P356
10.1111/J.1365-2141.1991.TB08007.X
P407
P577
1991-09-01T00:00:00Z